Trikafta is a 3-part drug that helps deltaF508 cystic fibrosis patients. Trikafta was approved by the FDA in 2019 based on studies testing efficacy and safety [1],[2]. The figure below illustrates mechanisms of action for a previous 2-part drug and the new 3-part drug.
Bad news though: the drug costs more than $300,000 per year (so research on more cost-effective solutions is critically important). Developing drugs like these costs a lot, and drug companies need to recoup costs and make a profit to justify investing in possible new drugs, so the FDA gives companies a 5-7 year monopoly when a drug is developed, before generic versions of drugs can be sold. The complex issues involved are covered well, I think, here.
You can find info about cystic fibrosis from the NIH, and current clinical trials here.
Here's an old but really interesting article about Cystic Fibrosis, and a source for up-to-date information on the disease and its effects on patients.